THOMAS KIENZLE / AFP
American biotech Moderna’s vaccine, Spikevax, has also been adapted as a bivalent vaccine against BA.1. This “Omicron BA.1” serum was approved in Canada as well as by the European Medicines Agency in early September.
COVID – The next generation anti-Covid vaccines, the so-called “bivalent”, arrive in France. The Minister of Health, François Braun, announced this Tuesday, September 27, on franceinfo that these booster doses of messenger RNA, developed by Pfizer/BioNTech and Moderna, will begin to be available. “From this Monday, October 3.” This in pharmacies and vaccination centers.
Only “Frail people, people over 60 years of age, health professionals and people in contact with frail people” they will be eligible from 3 months after their last reminder, confirmed François Braun. These vaccines were approved by the High Health Authority (HAS) on September 20, after approval by the European Medicines Agency (EMA) a few days earlier.
🗣 Covid: the beginning of the eighth wave? ➡️ “We have seen for three weeks a resumption of the circulation of the virus… https://t.co/R5WcWzInoy
– franceinfo (@franceinfo)
This date of October 3 is two weeks ahead of the calendar recommended by the HAS, which recommended in its opinion to “join this new campaign to the seasonal flu vaccination campaign that will begin on October 18,” remembering that “The concomitant injection of the two vaccines is possible, if it is carried out at two different injection sites. »
More effective vaccines?
According to a Moderna press release published on June 8, 2022, the results of this new bivalent vaccine are promising. 437 people were tested, half of the people received the initial virus vaccine as a booster and the other half received this new bivalent vaccine.
One month after injection, people vaccinated with the new strain show antibodies 8 times higher than others. According to the laboratory, the vaccine “demonstrates (…) also a greater response against the Omicron BA.4/5 sublines” compared to the first generation vaccine.
Regarding its ability to reduce the very strong contagiousness of this variant, “Nothing is certain at the moment but they could reduce the risk of transmission by 40 to 50%, which has not happened until now,” explained a few days ago HuffPost, Bruno Lina, virologist and member of the former Scientific Council. For his part, Professor Antoine Flahaut, director of the Institute for Global Health at the University of Geneva, said he was cautious with the “superiority” of these vaccines compared to earlier formulations.
Moderna’s Spikevax, only available at first
During the first days, only the 576,000 doses already received of Moderna’s Spikevax vaccine will be available in France. Several million other doses, including those from Pfizer, are expected by the end of October in the country. Those specifically adapted to BA.5, most of them in cases sequenced since June 2022, should not be available before November. “No supply voltage” it is anticipated by health authorities as this recall is entirely optional and only open to certain audiences at this time.
Call to ” common sense “ in the masks
A successful campaign could break the eighth wave, currently being seen in Western Europe. An increase in identified cases that is beginning to be reflected in the number of hospitalizations and resuscitations recorded in France, as can be seen in the graphs below.
The fourth booster dose is open to the most frail people and people over 60 years of age from mid-July. According to September 19 figures provided by Public Health France, only 36.4% of French people aged 80 (47.8% of those eligible since the last injection) and 28.7% of those aged 60 to 79 years (34.2% of those eligible) received their second booster. dose.
François Braun also asked ” regain common sense to wear a mask :: “When we are on top of each other, it is more reasonable to put on the mask. When you are with a very fragile person, you put on the mask.recommended.
See also on The HuffPost:
#vaccination #campaign #aimed #Omicron